ENDO (Endocrine Society Annual Meeting) 2026: key results and trends

Proptosis reduction of ≥3 mm occurred in 55% vs 3% and reduction of ≥4 mm occurred in 23% vs 0% of veligrotug vs placebo patients.

At-work productivity loss improved by 65% for participants in the palopegteriparatide treatment group during the DBP (lowering from 7.7% to 2.7%) and remained low (2.23%) through Week 156.

CAM2029-related adverse events (AEs) were reported by 17 (39.5%) patients; the most frequent were injection site AEs (12 [27.9%]).

The most common AEs (canvuparatide vs PBO) were headache (20.8% vs 6.3%), hypercalcemia (18.8% vs 6.3%), arthralgia (14.6% vs 0%), and nausea (12.5% vs 6.3%).

In the primary analysis, mean (95% CI) placebo-adjusted TG reductions from BL to W4 were 48% (2.7% to 92.9%; p=0.038) with 6 mg and 28% (-15.4% to 72.4%; p=0.193) with 12 mg.

Common adverse events (AEs; ≥25%) during 38 weeks of OLE bivamelagon, across all participants, were vomiting (53.8%), nausea (46.2%), and diarrhea (34.6%); of participants with those AEs, >80% were Grade 1 AEs.

In patients with cTED, treatment with MHB018A resulted in a proptosis response rate of 76% at week 24, with a mean change from baseline of -2.65 mm.

Incidence of adverse events (AEs) was similar for BMN 333 (35.7%) and placebo (33.3%); most were mild (grade 1; 9/42 [21.4%] and 2/18 [11.1%], respectively) or moderate (grade 2; 5/42 [11.9%] and 3/18 [16.7%], respectively).